Cargando…
Era of direct acting anti-viral agents for the treatment of hepatitis C
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone. Now we have stepped into the era of direct acting anti-viral agents (DAAs) against hepatitis C viru...
Autor principal: | Ahmed, Monjur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206157/ https://www.ncbi.nlm.nih.gov/pubmed/30386460 http://dx.doi.org/10.4254/wjh.v10.i10.670 |
Ejemplares similares
-
Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022) -
Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018) -
Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals
por: Cerrito, Lucia, et al.
Publicado: (2021) -
Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017) -
Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
por: Spera, Anna Maria
Publicado: (2022)